What was the market valuation of the China human growth-hormone market in 2024?

The market valuation was $517.5 Million in 2024. Read More

What is the projected market valuation for the China human growth-hormone market by 2035?

The projected valuation for 2035 is $1683.5 Million. Read More

What is the expected CAGR for the China human growth-hormone market during the forecast period 2025 - 2035?

The expected CAGR is 11.32% during the forecast period 2025 - 2035. Read More

What are the leading brands in the China human growth-hormone market and their valuations?

Leading brands include Genotropin at $400 Million, Norditropin at $320 Million, and Humatrope at $250 Million. Read More

What routes of administration are prevalent in the China human growth-hormone market?

The prevalent routes of administration include Subcutaneous at $650 Million, Intramuscular at $500 Million, and Intravenous at $533.5 Million. Read More

What applications are driving the demand for human growth hormone in China?

Key applications include Adult Growth Hormone Deficiency at $252.525 Million and Pediatric Growth Hormone Deficiency at $168.35 Million. Read More

How are human growth hormones distributed in China?

Distribution channels include Retail Pharmacies at $500 Million and Specialty Pharmacy at $533.5 Million. Read More

What is the market performance of the 'Others' segment in the brand category?

The 'Others' segment in the brand category shows a valuation range from $67.5 Million to $263.5 Million. Read More

What is the market size for the 'Small for Gestational Age' application in the China human growth-hormone market?

The market size for the 'Small for Gestational Age' application ranges from $25.875 Million to $84.225 Million. Read More

China Human Growth Hormone Market

Q: Which companies are considered key players in the China human growth-hormone market?

Key players include Pfizer Inc, Eli Lilly and Company, Merck KGaA, Novartis AG, Boehringer Ingelheim GmbH, Sandoz International GmbH, HGH Medical, and Genotropin. Read More

ID: MRFR/HC/43252-HCR

200 Pages

Satyendra Maurya

Last Updated: April 06, 2026

China Human Growth Hormone Market Research Report By Brand (Norditropin, Genotropin, Humatrope, Saizen, Omnitrope, Skytrofa, Others), By Route of Administration (Subcutaneous, Intramuscular, Intravenous), By Application (Pediatric Growth Hormone Deficiency, Adult Growth Hormone Deficiency, Idiopathic Growth Hormone Deficiency, Small for Gestational Age, Turner Syndrome, Prader-Willi Syndrome, Others) and By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacy, Specialty Pharmacy) - Growth & Industry Forecast 2025 To 2035

China Human Growth Hormone Market

Market Size

Forecast Period2025 - 2035

CAGR (2025 - 2035)11.32%

2024 Market Size$ 517.5 Million

2025 Market Size$ 576.08 Million

2035 Market Size$ 1,683.5 Million

Key Players

Pfizer Inc

Eli Lilly and Company

Merck KGaA

Novartis AG

Boehringer Ingelheim GmbH

Sandoz International GmbH

Trends

Rising Demand for Anti-Aging Treatments
Technological Advancements in Delivery Methods
Increased Focus on Regulatory Compliance

Opportunities

Rising Incidence of Growth Disorders
Growing Awareness of Health and Wellness
Cultural Shift Towards Preventive Healthcare

Summary Table of Contents Segmentation Download PDF

Certified Researchers

Customize Report

1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
1. 1.1 EXECUTIVE SUMMARY
  1. 1.1.1 Market Overview
  2. 1.1.2 Key Findings
  3. 1.1.3 Market Segmentation
  4. 1.1.4 Competitive Landscape
  5. 1.1.5 Challenges and Opportunities
  6. 1.1.6 Future Outlook
2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
1. 2.1 MARKET INTRODUCTION
  1. 2.1.1 Definition
  2. 2.1.2 Scope of the study
    1. 2.1.2.1 Research Objective
    2. 2.1.2.2 Assumption
    3. 2.1.2.3 Limitations
2. 2.2 RESEARCH METHODOLOGY
  1. 2.2.1 Overview
  2. 2.2.2 Data Mining
  3. 2.2.3 Secondary Research
  4. 2.2.4 Primary Research
    1. 2.2.4.1 Primary Interviews and Information Gathering Process
    2. 2.2.4.2 Breakdown of Primary Respondents
  5. 2.2.5 Forecasting Model
  6. 2.2.6 Market Size Estimation
    1. 2.2.6.1 Bottom-Up Approach
    2. 2.2.6.2 Top-Down Approach
  7. 2.2.7 Data Triangulation
  8. 2.2.8 Validation
3 SECTION III: QUALITATIVE ANALYSIS
1. 3.1 MARKET DYNAMICS
  1. 3.1.1 Overview
  2. 3.1.2 Drivers
  3. 3.1.3 Restraints
  4. 3.1.4 Opportunities
2. 3.2 MARKET FACTOR ANALYSIS
  1. 3.2.1 Value chain Analysis
  2. 3.2.2 Porter's Five Forces Analysis
    1. 3.2.2.1 Bargaining Power of Suppliers
    2. 3.2.2.2 Bargaining Power of Buyers
    3. 3.2.2.3 Threat of New Entrants
    4. 3.2.2.4 Threat of Substitutes
    5. 3.2.2.5 Intensity of Rivalry
  3. 3.2.3 COVID-19 Impact Analysis
    1. 3.2.3.1 Market Impact Analysis
    2. 3.2.3.2 Regional Impact
    3. 3.2.3.3 Opportunity and Threat Analysis
4 SECTION IV: QUANTITATIVE ANALYSIS
1. 4.1 Life Sciences, BY Brand (USD Million)
  1. 4.1.1 Norditropin
  2. 4.1.2 Genotropin
  3. 4.1.3 Humatrope
  4. 4.1.4 Saizen
  5. 4.1.5 Omnitrope
  6. 4.1.6 Skytrofa
  7. 4.1.7 Others
2. 4.2 Life Sciences, BY Route of Administration (USD Million)
  1. 4.2.1 Subcutaneous
  2. 4.2.2 Intramuscular
  3. 4.2.3 Intravenous
3. 4.3 Life Sciences, BY Application (USD Million)
  1. 4.3.1 Pediatric Growth Hormone Deficiency
  2. 4.3.2 Adult Growth Hormone Deficiency
  3. 4.3.3 Idiopathic Growth Hormone Deficiency
  4. 4.3.4 Small for Gestational Age
  5. 4.3.5 Turner Syndrome
  6. 4.3.6 Prader-Willi Syndrome
  7. 4.3.7 Others
4. 4.4 Life Sciences, BY Distribution Channel (USD Million)
  1. 4.4.1 Hospital Pharmacies
  2. 4.4.2 Retail Pharmacies
  3. 4.4.3 Online Pharmacy
  4. 4.4.4 Specialty Pharmacy
5 SECTION V: COMPETITIVE ANALYSIS
1. 5.1 Competitive Landscape
  1. 5.1.1 Overview
  2. 5.1.2 Competitive Analysis
  3. 5.1.3 Market share Analysis
  4. 5.1.4 Major Growth Strategy in the Life Sciences
  5. 5.1.5 Competitive Benchmarking
  6. 5.1.6 Leading Players in Terms of Number of Developments in the Life Sciences
  7. 5.1.7 Key developments and growth strategies
    1. 5.1.7.1 New Product Launch/Service Deployment
    2. 5.1.7.2 Merger & Acquisitions
    3. 5.1.7.3 Joint Ventures
  8. 5.1.8 Major Players Financial Matrix
    1. 5.1.8.1 Sales and Operating Income
    2. 5.1.8.2 Major Players R&D Expenditure. 2023
2. 5.2 Company Profiles
  1. 5.2.1 Pfizer Inc (US)
    1. 5.2.1.1 Financial Overview
    2. 5.2.1.2 Products Offered
    3. 5.2.1.3 Key Developments
    4. 5.2.1.4 SWOT Analysis
    5. 5.2.1.5 Key Strategies
  2. 5.2.2 Eli Lilly and Company (US)
    1. 5.2.2.1 Financial Overview
    2. 5.2.2.2 Products Offered
    3. 5.2.2.3 Key Developments
    4. 5.2.2.4 SWOT Analysis
    5. 5.2.2.5 Key Strategies
  3. 5.2.3 Merck KGaA (DE)
    1. 5.2.3.1 Financial Overview
    2. 5.2.3.2 Products Offered
    3. 5.2.3.3 Key Developments
    4. 5.2.3.4 SWOT Analysis
    5. 5.2.3.5 Key Strategies
  4. 5.2.4 Novartis AG (CH)
    1. 5.2.4.1 Financial Overview
    2. 5.2.4.2 Products Offered
    3. 5.2.4.3 Key Developments
    4. 5.2.4.4 SWOT Analysis
    5. 5.2.4.5 Key Strategies
  5. 5.2.5 Boehringer Ingelheim GmbH (DE)
    1. 5.2.5.1 Financial Overview
    2. 5.2.5.2 Products Offered
    3. 5.2.5.3 Key Developments
    4. 5.2.5.4 SWOT Analysis
    5. 5.2.5.5 Key Strategies
  6. 5.2.6 Sandoz International GmbH (CH)
    1. 5.2.6.1 Financial Overview
    2. 5.2.6.2 Products Offered
    3. 5.2.6.3 Key Developments
    4. 5.2.6.4 SWOT Analysis
    5. 5.2.6.5 Key Strategies
  7. 5.2.7 HGH Medical (US)
    1. 5.2.7.1 Financial Overview
    2. 5.2.7.2 Products Offered
    3. 5.2.7.3 Key Developments
    4. 5.2.7.4 SWOT Analysis
    5. 5.2.7.5 Key Strategies
  8. 5.2.8 Genotropin (US)
    1. 5.2.8.1 Financial Overview
    2. 5.2.8.2 Products Offered
    3. 5.2.8.3 Key Developments
    4. 5.2.8.4 SWOT Analysis
    5. 5.2.8.5 Key Strategies
3. 5.3 Appendix
  1. 5.3.1 References
  2. 5.3.2 Related Reports
6 LIST OF FIGURES
1. 6.1 MARKET SYNOPSIS
2. 6.2 CHINA MARKET ANALYSIS BY BRAND
3. 6.3 CHINA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
4. 6.4 CHINA MARKET ANALYSIS BY APPLICATION
5. 6.5 CHINA MARKET ANALYSIS BY DISTRIBUTION CHANNEL
6. 6.6 KEY BUYING CRITERIA OF LIFE SCIENCES
7. 6.7 RESEARCH PROCESS OF MRFR
8. 6.8 DRO ANALYSIS OF LIFE SCIENCES
9. 6.9 DRIVERS IMPACT ANALYSIS: LIFE SCIENCES
10. 6.10 RESTRAINTS IMPACT ANALYSIS: LIFE SCIENCES
11. 6.11 SUPPLY / VALUE CHAIN: LIFE SCIENCES
12. 6.12 LIFE SCIENCES, BY BRAND, 2024 (% SHARE)
13. 6.13 LIFE SCIENCES, BY BRAND, 2024 TO 2035 (USD Million)
14. 6.14 LIFE SCIENCES, BY ROUTE OF ADMINISTRATION, 2024 (% SHARE)
15. 6.15 LIFE SCIENCES, BY ROUTE OF ADMINISTRATION, 2024 TO 2035 (USD Million)
16. 6.16 LIFE SCIENCES, BY APPLICATION, 2024 (% SHARE)
17. 6.17 LIFE SCIENCES, BY APPLICATION, 2024 TO 2035 (USD Million)
18. 6.18 LIFE SCIENCES, BY DISTRIBUTION CHANNEL, 2024 (% SHARE)
19. 6.19 LIFE SCIENCES, BY DISTRIBUTION CHANNEL, 2024 TO 2035 (USD Million)
20. 6.20 BENCHMARKING OF MAJOR COMPETITORS
7 LIST OF TABLES
1. 7.1 LIST OF ASSUMPTIONS
7.1.1
1. 7.2 China MARKET SIZE ESTIMATES; FORECAST
  1. 7.2.1 BY BRAND, 2025-2035 (USD Million)
  2. 7.2.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Million)
  3. 7.2.3 BY APPLICATION, 2025-2035 (USD Million)
  4. 7.2.4 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Million)
2. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
7.3.1
1. 7.4 ACQUISITION/PARTNERSHIP
7.4.1

Certified Researchers

Customize Report

China Life Sciences Market Segmentation

Life Sciences By Brand (USD Million, 2025-2035)

Norditropin
Genotropin
Humatrope
Saizen
Omnitrope
Skytrofa
Others

Life Sciences By Route of Administration (USD Million, 2025-2035)

Subcutaneous
Intramuscular
Intravenous

Life Sciences By Application (USD Million, 2025-2035)

Pediatric Growth Hormone Deficiency
Adult Growth Hormone Deficiency
Idiopathic Growth Hormone Deficiency
Small for Gestational Age
Turner Syndrome
Prader-Willi Syndrome
Others

Life Sciences By Distribution Channel (USD Million, 2025-2035)

Hospital Pharmacies
Retail Pharmacies
Online Pharmacy
Specialty Pharmacy

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”